UPDATE: SVB Leerink On Nurix Outperform Reiteration: Firm Notes Co. Has 'Started Dose Escalation Portion Of NX-1607 Phase 1A/B Study Design' & Sees Phase 1 Trial Initiation For DeTIL-0255 Possible Within FY21; Believes De-Risking NX-1607 Helpful To Thesis